When was BioSynesis founded?

BioSynesis was founded in 2013 and raised its 1st funding round 2 years after it was founded.

Where is BioSynesis located?

BioSynesis is headquartered in San Francisco, United States.

How many employees does BioSynesis have?

As of May 31, 2026, the latest employee count at BioSynesis is 2.

Is BioSynesis a funded company?

BioSynesis is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Mar 01, 2015.

When was the latest funding round of BioSynesis?

BioSynesis' latest funding was a $***** Grant (prize money) round on Aug 03, 2022, with participation from 1 investor. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $685M in funding in 2026 to date.

Where does BioSynesis rank among its competitors?

BioSynesis ranks 14th amongst 29 active competitors, of which 8 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was F2g, which secured $100M in Sep, 2024.

Who are the top competitors of BioSynesis?

BioSynesis' top competitors include Scynexis, F2g and Pulmocide. Among them, F2g secured the most recent funding round in September, 2024.

BioSynesis - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of biofilm-specific therapeutics for the treatment of infectious diseases. The company is developing biofilm-specific therapeutics as novel treatments against fungal pathogens such as Candida albicans biofilm infections.

Website: biosynesis.com
Email ID: *****@biosynesis.com
Phone Number: +1 **********

Key Metrics

Founded Year

2013

Location

San Francisco, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Aug 03, 2022, $*****

Investors

HHS

Ranked

14^th among 29 active competitors

Employee Count

2 as on May 31, 2026

Similar Companies

Scynexis & 36 more

View BioSynesis' full profile

BioSynesis has raised funding over 3 rounds. Its first funding round was on Mar 01, 2015. Its latest funding round was a Grant (prize money) round on Aug 03, 2022 for $*****. 1 investor participated in its latest round. BioSynesis has 1 institutional investor.

Here is the list of recent funding rounds of BioSynesis:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 03, 2022	2662946	Grant (prize money)	8987844	8031265	1666334	1126269
Feb 15, 2017	5970102	Grant (prize money)	4121162	9851640	5131126	HHS
Mar 01, 2015	8328935	Grant (prize money)	6842000	1439604	4851967	HHS

Access funding benchmarks and valuations. Sign up today!

View details of BioSynesis's funding rounds and investors

The founders of BioSynesis is Clarissa Nobile.

Here are the details of BioSynesis' key team members:

Clarissa Nobile: Founder & CEO of BioSynesis.
Contact Info: 1 email address

View details of BioSynesis's Founder profiles and Board Members

BioSynesis' employee count trend

BioSynesis has 2 employees as of May 26. Here is BioSynesis's employee count trend over the years:

Uncover BioSynesis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioSynesis include Scynexis, F2g and Pulmocide. Here is the list of Top 10 competitors of BioSynesis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Scynexis 1999, Jersey City (United States), Public	Developing glucan synthase inhibitors for the treatment of fungal infections.	$62.7M	Societe Generale, KBL & 14 others	70/100
2nd	F2g 1998, Manchester (United Kingdom), Series H	Developer of therapeutic treatments for rare and life threatening infections	$353M	Morningside, Advent Life Sciences & 21 others	61/100
3rd	Pulmocide 2013, London (United Kingdom), Series C	Developer of inhaled antifungal medicines for treating respiratory lung infections	$205M	Pictet Group, Vivo Capital & 15 others	55/100
4th	Biosergen 2004, Solna (Sweden), Funding Raised	Developer of anti-fungal therapeutics for fungal infections	-	Rosetta Capital, BtoV	45/100
5th	Viamet Pharmaceuticals 2005, Durham (United States), Acqui-Hired	Innovation hub revolutionizing healthcare, education, safety, energy, and technology with AI	$161M	Defense.gov, Woodford Investment Management ... & 7 others	41/100
6th	Amplyx Pharmaceuticals 2006, San Diego (United States), Acqui-Hired	Pharmaceutical company focused on innovative medicines, vaccines, and expanded access programs	$144M	RiverVest Venture Partners, Sofinnova Investments ... & 16 others	41/100
7th	Elion Therapeutics 2024, New York City (United States), Series B	Developer of therapeutics for invasive fungal infections	$81M	Deerfield, AMR Action Fund & 1 others	39/100
8th	Mycovia Pharmaceuticals 2018, Durham (United States), Funding Raised	Developer of small molecule based therapeutics for the treatment of recurrent vulvovaginal candidiasis	-	NovaQuest Capital Management, HHS	32/100
9th	Hallux 2012, Laguna Hills (United States), Series B	Provider of subungual drug delivery technology for onychomycosis	$27.2M	Deerfield, OrthoArizona	32/100
10th	Morphobloc 2016, Umea (Sweden), Unfunded	Developer of antifungal agents to treat fungal diseases	-	-	30/100
14th	BioSynesis 2013, San Francisco (United States), Funding Raised	Developer of biofilm-specific therapeutics for the treatment of infectious diseases	-	HHS	29/100